Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalating Study Of SU014813 In Patients With Solid Tumors Not Amenable To Conventional Therapy

NCT00982267 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00982267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00982267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalating Study Of SU014813 In Patients With Solid Tumors Not Amenable To Conventional Therapy
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2003
Completion date
June 30, 2011
Enrollment
77 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, solid tumors